Search

Your search keyword '"Soni, Suneeta"' showing total 131 results
Start Over Author "Soni, Suneeta"
131 results on '"Soni, Suneeta"'

4. Retrospective testing for mpox virus in routine STI screens from men who have sex with men in England, August–October 2022

Author

Pitt-Kendall, Rachel, primary, Foster, Clare, additional, Rayment, Michael, additional, Orzechowska, Beata, additional, Mammadov, Rufat, additional, Soni, Suneeta, additional, Mortlock, Simon, additional, Owen, Jodie, additional, Uglow, Luke, additional, Day, Michaela Joanne, additional, Rai Gurung, Rupa, additional, Savary-Trathen, Amber, additional, Jenkins, Rhian, additional, McGuire, Emma, additional, Gordon, Natalie, additional, Day, Sara Louise, additional, Kelly, Adrian M, additional, Goward, Charlotte, additional, Folkard, Kate, additional, Charles, Hannah, additional, Mohammed, Hamish, additional, Brown, Colin S, additional, and Fifer, Helen, additional

Published
2023
Full Text
View/download PDF

5. Surveillance of Mpox Cases Attending Sexual Health Services in England (SOMASS): design, implementation and initial findings from the SOMASS data collection tool, 2022

Author

Charles, Hannah, primary, Prochazka, Mateo, additional, Murray, Judith, additional, Sexual Health Liaison Group, UKHSA, additional, Soni, Suneeta, additional, Haddow, Lewis, additional, Beets, Katie, additional, Pilkington, Victoria, additional, Low, Nicola, additional, Candfield, Sophie, additional, Jones, Rachael, additional, Bleiker, Tanya, additional, Dewsnap, Claire, additional, Phillips, Matt, additional, and Phillips, David, additional

Published
2023
Full Text
View/download PDF

7. Treating Mycoplasma genitalium(in pregnancy): a social and reproductive justice concern

Author

McKnight, Ulla, Farsides, Bobbie, Soni, Suneeta, and Will, Catherine

Abstract

Antimicrobial Resistance is a threat to individual and to population health and to future generations, requiring “collective sacrifices” in order to preserve antibiotic efficacy. ‘Who shouldmake the sacrifices?’ and ‘Who willmost likely make them?’ are ethical concerns posited as potentially manageable through Antimicrobial Stewardship. Antimicrobial stewardship almost inevitably involves a form of clinical cost-benefit analysis that assesses the possible effects of antibiotics to treat a diagnosed infection in a particular patient. However, this process rarely accounts properly for patients – above and beyond assessments of potential (non)compliance or adherence to care regimes. Drawing on a vignette of a pregnant woman of colour and migrant diagnosed with Mycoplasma genitalium, a sexually transmissible bacterium, this article draws out some of the ethical, speculative, and practical tensions and complexities involved in Antimicrobial Stewardship. We argue that patients also engage in a form of cost-benefit analysis influenced by experiences of reproductive and social (in)justice and comprising speculative variables - to anticipate future possibilities. These processes have the potential to have effects above and beyond the specific infection antimicrobial stewardship was activated to address. We contend that efforts to practice and research antimicrobial stewardship should accommodate and incorporate these variables and acknowledge the structures they emerge with(in), even if their components remain unknown. This would involve recognising that antimicrobial stewardship is intricately connected to other social justice issues such as immigration policy, economic justice, access to appropriate medical care, racism, etc.

Published
2024
Full Text
View/download PDF

25. Resistance-guided treatment of infection at a UK sexual health centre.

Author

Conway, Ruairi JH, Cook, Seamus, Malone, Cassandra, Bone, Simon, Hassan-Ibrahim, Mohammed Osman, and Soni, Suneeta

Abstract

We evaluated the ResistancePlus® MG assay in providing macrolide resistance-guided treatment (RGT) for Mycoplasma genitalium infection at a UK sexual health centre. M. genitalium-positive samples from men with urethritis and women with pelvic inflammatory disease (PID) were tested for macrolide resistance-mediating mutations (MRMMs). MRMM-positive infections were given moxifloxacin 400 mg; otherwise 2 g azithromycin (1 g single dose and then 500 mg OD) was given. Among 57 M. genitalium-positive patients (32 men and 25 women), MRMMs were detected in 41/57 (72% [95% confidence interval (95% CI) 58-83%). Thirty-two of 43 patients given RGT attended for test of cure. Treatment failure rate was significantly lower at 1/32 (3%) than 10/37 (27%) before RGT (n = 37 [men = 23 and women = 17]; p = 0.008). Treatment failure was lower in male urethritis (0/15 vs. 7/21 p = 0.027) but not in female PID. There was a trend of a shorter time to negative test of cure (TOC) in male urethritis (55.1 [95% 43.7-66.4] vs. 85.1 [95% CI CI 64.1-106.0] days, p = 0.077) but not in female PID. Macrolide resistance is higher than previous UK reports and higher than expected. RGT reduces overall treatment failure and is particularly beneficial in M. genitalium urethritis. Fluoroquinolone resistance will continue to rise with increasing fluoroquinolone use, and RGT is critical to direct appropriate azithromycin use and prevent overuse of moxifloxacin. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

26. Treatment of mild-to-moderate pelvic inflammatory disease with a short-course azithromycin-based regimen versus ofloxacin plus metronidazole: results of a multicentre, randomised controlled trial.

Author

Dean, Gillian, Soni, Suneeta, Pitt, Rachel, Ross, Jonathan, Sabin, Caroline, and Whetham, Jennifer

Abstract

Objective: A multicentre, randomised non-inferiority trial compared the efficacy and safety of 14 days of ofloxacin and metronidazole (standard-of-care (SoC)) versus a single dose of intramuscular ceftriaxone followed by 5 days of azithromycin and metronidazole (intervention arm (IA)) in women with mild-to-moderate pelvic inflammatory disease (PID).Methods: Women with a clinical diagnosis of PID presenting at sexual health services were randomised to the SoC or IA arms. Treating clinicians and participants were not blinded to treatment allocation but the clinician performing the assessment of primary outcome was blinded. The primary outcome was clinical cure defined as ≥70% reduction in the modified McCormack pain score at day 14-21 after starting treatment. Secondary outcomes included adherence, tolerability and microbiological cure.Results: Of the randomised population 72/153 (47.1%) reached the primary end point in the SoC arm, compared with 68/160 (42.5%) in the IA (difference in cure 4.6% (95% CI -15.6% to 6.5%). Following exclusion of 86 women who were lost to follow-up, attended outside the day 14-21 follow-up period, or withdrew consent, 72/107 (67.3%) had clinical cure in the SoC arm compared with 68/120 (56.7%) in the IA, giving a difference in cure rate of 10.6% (95% CI -23.2% to 1.9%). We were unable to demonstrate non-inferiority of the IA compared with SoC arm. Women in the IA took more treatment doses compared with the SoC group (113/124 (91%) vs 75/117 (64%), p=0.0001), but were more likely to experience diarrhoea (61% vs 24%, p<0.0001). Of 288 samples available for analysis, Mycoplasma genitalium was identified in 10% (28/288), 58% (11/19) of which had baseline antimicrobial resistance-associated mutations.Conclusion: A short-course azithromycin-based regimen is likely to be less effective than the standard treatment with ofloxacin plus metronidazole. The high rate of baseline antimicrobial resistance supports resistance testing in those with M. genitalium infection to guide appropriate therapy.Trial Registration Number: 2010-023254-36. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

45. British Association for Sexual Health and HIV national guideline for the management of infection with (2018).

Author

Soni, Suneeta, Horner, Paddy, Rayment, Michael, Pinto-Sander, Nicolas, Naous, Nadia, Parkhouse, Andy, Bancroft, Darren, Patterson, Carl, and Fifer, Helen

Subjects
SEXUALLY transmitted diseases, SEXUAL health, MYCOPLASMA, HIV, OLDER people
Abstract

This is the first British Association for Sexual Health and HIV (BASHH) guideline for the diagnosis and management of Mycoplasma genitalium in people aged 16 years and older. The guideline is primarily aimed at level 3 sexually transmitted infection (STI) management services within the UK, although it could also serve as a reference guide for STI services at other levels. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results